

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**SCHEDULE 14A**

**PROXY STATEMENT PURSUANT TO SECTION 14(a) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to § 240.14a-12

**BIOGEN IDEC INC.**


(Name of Registrant as Specified In Its Charter)

**N.A.**

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  - (1) Title of each class of securities to which transaction applies:
  - (2) Aggregate number of securities to which transaction applies:
  - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
  - (4) Proposed maximum aggregate value of transaction:
  - (5) Total fee paid:
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  - (1) Amount Previously Paid:
  - (2) Form, Schedule or Registration Statement No.:
  - (3) Filing Party:
  - (4) Date Filed:



## **Biogen Idec R&D Strategy**

*Cecil B. Pickett, PhD  
President, Research & Development*

*March 25, 2009*

**biogen ideo**

# Forward Looking Statements and Important Information

---

This presentation includes forward-looking statements about:

- estimates of the market potential for our product candidates
- our expected filings with regulatory agencies
- the anticipated development and timing of programs in our clinical pipeline

Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those that we express or imply, including the uncertainty of success in commercializing our products, the occurrence of adverse safety events with our products, competitive pressures, our dependence on collaborations over which we may not always have full control, our ability to attract and retain qualified personnel, our ability to protect our intellectual property rights and the cost of doing so, product liability claims, and the other risks and uncertainties that are described in Item 1.A. Risk Factors in our annual report on Form 10-K and in other reports we file with the SEC.

These forward-looking statements speak only as of the date of this presentation, and we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Biogen Idec and its directors, executive officers and other members of its management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Biogen Idec in connection with the Company's 2009 annual meeting of stockholders. Information concerning the interests of participants in the solicitation of proxies will be included in any proxy statement filed by Biogen Idec in connection with the Company's 2009 annual meeting of stockholders.

In addition, Biogen Idec files annual, quarterly and special reports with the Securities and Exchange Commission (the "SEC"). The proxy statements and other reports, when available, can be obtained free of charge at the SEC's web site at [www.sec.gov](http://www.sec.gov) or from Biogen Idec at [www.biogenidec.com](http://www.biogenidec.com). Biogen Idec stockholders are advised to read carefully any proxy statement filed in connection with the Company's 2009 annual meeting of stockholders when it becomes available before making any voting or investment decision. The Company's proxy statement will also be available for free by writing to Biogen Idec Inc., 14 Cambridge Center, Cambridge, MA 02142. In addition, copies of the proxy materials may be requested from our proxy solicitor, Innisfree M&A Incorporated, by toll-free telephone at (877) 750-5836 or by e-mail at [info@innisfreema.com](mailto:info@innisfreema.com).

biogen idec

---


# Biogen Idec R&D Strengths

---


- Strong R&D fundamentals
  - World class biotherapeutic discovery and development organization
- Focused drug discovery and development efforts
  - Neurology
  - Immunology
  - Oncology
  - Cardiology
- Strong link between discovery research, clinical development, and strategic business units
- Proven track record of discovering and developing innovative molecules
- Extensive biologic manufacturing expertise

# R&D Strategy

---



## Goal of Strong Growth in Registrational Programs



## Independent Assessment by Moody's – Highest Quality Late Stage Pipeline

- Moody's Investors Service research
- Issuer Scorecard: Large U.S. Pharmaceutical Companies published February 2009
  - Most recent rating methodology mapping for 12 large U.S.-based pharmaceutical and biotech companies
  - Ranking of the 12 companies from strongest to weakest on several important criteria
- Biogen Idec ranked
  - Highest on late-stage pipeline quality
  - Top third on pipeline diversity, within the most diverse category
- Additional details at [www.moodys.com](http://www.moodys.com)


Biogen Idec (Baa3)	54.3%
Allergan (A3)	31.8%
Schering-Plough (Baa1)	27.7%
J&J (Aaa) / Pharma Only**	27.5%
Amgen (A3)	23.8%
Genentech (A1*)	21.0%
Wyeth (A3*)	20.1%
Eli Lilly & Company (A1)	18.8%
Bristol-Myers Squibb (A2)	16.8%
Merck & Co., Inc. (Aa3)	16.5%
Abbott (A1) / Pharma Only**	14.2%
J&J (Aaa) / Total Company**	11.4%
Abbott (A1) / Total Company**	11.4%
Pfizer (Aa1*)	10.0%

= Highest score (> 30%)  
 = Lowest score (< 15%)

\* Ratings under review  
 \*\* Ratios shown on both bases for J&J and Abbott



# Delivering Data Readouts and Decision Points






# Patents and Publications

## 5,763 Total Biogen Idec Patents



## 89 Peer Reviewed Publications in 2008

### Recent Patents




### 2008 Publications



## R&D Organization Summary

---

- Outstanding people at all levels in the R&D Organization
- Robust pipeline with important compounds at all stages of development
- World-class expertise in discovery and development of biologics
- Focus on executing clinical trials
  - Continue developing compounds in registrational programs
  - Move earlier programs rapidly to proof-of-concept



## **Biogen Idec Pipeline Summary**

*Cecil B. Pickett, PhD  
President, Research & Development*

*March 25, 2009*





**biogen ideo**

## Robust Pipeline – Late, Early, Discovery

---

- Product pipeline significantly strengthened over past three years
  - More than 20 programs added to the clinical pipeline or advanced to next clinical step since the start of 2007
  - More than ten molecules accessed via business development strategy
- 60 clinical trials ongoing
  - More than four fold increase in patients enrolled in clinical trials since 2007
  - 15 indications across neurology, oncology, immunology, cardiopulmonary and hemophilia
- Seven programs currently in registrational trials and filing
- 20 programs in Phase 2 or beyond
- More than 35 preclinical and discovery research programs

# Late Stage Pipeline







Seven programs in registrational trials and filing

▶ January 2007 Pipeline
 ▶ 2007 and 2008 Progress




# Early Stage Pipeline



20 Programs  
in Phase 2  
and Beyond

▶ January 2007 Pipeline
 ▶ 2007 and 2008 Progress





## **Biogen Idec Research & Development Day**

*March 25, 2009*

**biogen idec**